Evidence map›Paper›PMID 28783671›Full record

ArticleScience immunology2017

Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

LaTonya D Williams, Gilad Ofek, Sebastian Schätzle, Jonathan R McDaniel, Xiaozhi Lu, Nathan I Nicely, Liming Wu, Caleb S Lougheed, Todd Bradley, Mark K Louder and 31 more

Open access · greenAbstract read
In one paragraph

Article in Science immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 1 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Structural basis of membrane engagement and polyreactivity control in HIV-1 MPER broadly neutralizing antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Conformational Variability of HIV-1 Env Trimer and Viral Vulnerability.bioRxiv : the preprint server for biology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 11 institutions in 2 countries.

LaTonya D WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Gilad OfekInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Sebastian SchätzleDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Jonathan R McDanielDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Xiaozhi LuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Nathan I NicelyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Liming WuInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Caleb S LougheedInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Todd BradleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Mark K LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Krisha McKeeVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Robert T BailerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Sijy O'DellVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Ivelin S GeorgievVanderbilt Vaccine Center and Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Michael S SeamanBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Robert J ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Dawn J MarshallDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kara AnastiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Guang YangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Xiaoyan NieDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Nancy L TumbaCentre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kshitij WaghTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Bette KorberTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Thomas B KeplerDepartments of Microbiology and Mathematics & Statistics, Boston University School of Medicine, Boston, MA 02118, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Lynn MorrisCentre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Gift KamangaUniversity of North Carolina Project-Malawi, Kamuzu Central Hospital, Lilongwe, Malawi.
Myron S CohenDepartments of Medicine, Epidemiology, and Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Shi-Mao XiaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Garnett KelsoeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Feng GaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
George GeorgiouDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA. barton.haynes@dm.duke.edu gg@che.utexas.edu.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@dm.duke.edu gg@che.utexas.edu.
Duke University · USNational Institutes of Health · USThe University of Texas at Austin · USLos Alamos National Laboratory · USNational Institute for Communicable DiseasesNational Institute of Allergy and Infectious Diseases · USHarvard University · USKamuzu Central Hospital · MWNational Institute of Standards and Technology · USUniversity of Maryland, Baltimore · USUniversity of Maryland, College Park · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
Measurement of HIV Neutralization Using Quantitative AssaysZIAAI005010 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$7.6M
NIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI064518NIAID NIH HHS T32 AI007392NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

Induction of broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development. Antibody 10E8, reactive with the distal portion of the membrane-proximal external region (MPER) of HIV-1 gp41, is broadly neutralizing. However, the ontogeny of distal MPER antibodies and the relationship of memory B cell to plasma bnAbs are poorly understood. HIV-1-specific memory B cell flow sorting and proteomic identification of anti-MPER plasma antibodies from an HIV-1-infected individual were used to isolate broadly neutralizing distal MPER bnAbs of the same B cell clonal lineage. Structural analysis demonstrated that antibodies from memory B cells and plasma recognized the envelope gp41 bnAb epitope in a distinct orientation compared with other distal MPER bnAbs. The unmutated common ancestor of this distal MPER bnAb was autoreactive, suggesting lineage immune tolerance control. Construction of chimeric antibodies of memory B cell and plasma antibodies yielded a bnAb that potently neutralized most HIV-1 strains.

Identifiers

PMID28783671
PMCPMC5905719
OpenAlexW2579899292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.